Market Cap 718.40M
Revenue (ttm) 568.09M
Net Income (ttm) 22.73M
EPS (ttm) N/A
PE Ratio 11.35
Forward PE 10.98
Profit Margin 4.00%
Debt to Equity Ratio 1.16
Volume 370,700
Avg Vol 581,512
Day's Range N/A - N/A
Shares Out 83.54M
Stochastic %K 29%
Beta 0.67
Analysts Strong Sell
Price Target $14.80

Company Profile

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted...

Industry: Medical Devices
Sector: Healthcare
Phone: 919 474 6700
Address:
4721 Emperor Boulevard, Suite 100, Durham, United States
MarketBeat
MarketBeat Jun. 8 at 11:04 PM
https://marketbeat.com/a/8701425/ $BVS Bioventus Highlights PNS, PRP Growth as Cash Flow Improves and Debt Falls
0 · Reply
Hope2retire
Hope2retire Jun. 1 at 6:01 PM
$BVS It's go to bottom out somewhere here! And someone's gotta start buying this up. I'm buying what I can, but I don't have the juice to make it move. Waiting on the makers. Still bullish on $BVS
1 · Reply
metrostock
metrostock May. 29 at 6:14 PM
$BVS why are trades in the single digits ? Is there manipulation happening ?
0 · Reply
Hope2retire
Hope2retire May. 27 at 4:57 PM
$BVS No news, no catalyst at all to justify this! I don't know why I still bother with any healthcare stocks! They never fail to fail! Someone is gradually dumping heavy chunks over the last 4 or 5 days. Derisking, I guess. Either way, something's got to turn around! And quick!!
2 · Reply
theDIOyears
theDIOyears May. 27 at 2:32 PM
$BVS the bleeding continues. Why? Makes no sense. Someone have any other insight into this action?
1 · Reply
gazza01
gazza01 May. 23 at 1:41 AM
$BVS or maybe it was the results in the Cartistem phrase 3 that showed disease modification in knee OA?
1 · Reply
gazza01
gazza01 May. 22 at 12:03 PM
$BVS I wonder if the drop is derisking, as the results expected in May, for the Australian knee OA stock Cynata ASX:CYP? Their results are targeting disease modification for OA, not just pain relief... If successful, the CYP trial would wipe out treatments just providing pain relief such as hyaluronic acid injections.
0 · Reply
Doozio
Doozio May. 21 at 9:35 PM
$BVS maybe they wud extended a 🐑 🪧 ONTO 🐒🍌🧠⏰♾️
1 · Reply
Doozio
Doozio May. 21 at 6:45 PM
$BVS ONTO 🐒🍌🧠⏰♾️
0 · Reply
gazza01
gazza01 May. 21 at 5:11 PM
$BVS Weird. Can't see any negative news...
1 · Reply
Latest News on BVS
Bioventus management to meet with Barrington

2026-06-16T20:08:51.000Z - 10 hours ago

Bioventus management to meet with Barrington


Bioventus Transcript: AGM 2026

Jun 3, 2026, 10:00 AM EDT - 13 days ago

Bioventus Transcript: AGM 2026


Bioventus reports Q1 EPS 15c, consensus 7c

2026-05-07T06:30:12.000Z - 5 weeks ago

Bioventus reports Q1 EPS 15c, consensus 7c


Bioventus Earnings Call Transcript: Q1 2026

May 6, 2026, 8:30 AM EDT - 5 weeks ago

Bioventus Earnings Call Transcript: Q1 2026


Bioventus Earnings release: Q1 2026

May 6, 2026, 8:30 AM EDT - 5 weeks ago

Bioventus Earnings release: Q1 2026


Bioventus Quarterly report: Q1 2026

May 6, 2026, 8:30 AM EDT - 5 weeks ago

Bioventus Quarterly report: Q1 2026


Bioventus Slides: Q1 2026

May 6, 2026, 8:30 AM EDT - 5 weeks ago

Bioventus Slides: Q1 2026


Bioventus Reports First Quarter Financial Results

May 6, 2026, 7:30 AM EDT - 5 weeks ago

Bioventus Reports First Quarter Financial Results


Bioventus Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 7 weeks ago

Bioventus Proxy statement: Proxy filing


Bioventus Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 7 weeks ago

Bioventus Proxy statement: Proxy filing


Bioventus initiated with an Outperform at CJS Securities

2026-03-27T13:00:51.000Z - 2 months ago

Bioventus initiated with an Outperform at CJS Securities


Bioventus Slides: Corporate presentation

Mar 16, 2026, 7:00 AM EDT - 3 months ago

Bioventus Slides: Corporate presentation


Bioventus management to meet with Barrington

2026-03-09T18:55:09.000Z - 3 months ago

Bioventus management to meet with Barrington


Bioventus price target raised to $16 from $15 at Craig-Hallum

2026-03-06T14:05:43.000Z - 3 months ago

Bioventus price target raised to $16 from $15 at Craig-Hallum


Bioventus price target raised to $14 from $13 at Barrington

2026-03-06T12:35:37.000Z - 3 months ago

Bioventus price target raised to $14 from $13 at Barrington


Bioventus Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:30 AM EST - 3 months ago

Bioventus Earnings Call Transcript: Q4 2025


Bioventus Annual report: Q4 2025

Mar 5, 2026, 8:30 AM EST - 3 months ago

Bioventus Annual report: Q4 2025


Bioventus Earnings release: Q4 2025

Mar 5, 2026, 8:30 AM EST - 3 months ago

Bioventus Earnings release: Q4 2025


Bioventus Slides: Q4 2025

Mar 5, 2026, 8:30 AM EST - 3 months ago

Bioventus Slides: Q4 2025


Bioventus sees FY26 adjusted EPS 73c-77c, consensus 77c

2026-03-05T12:21:28.000Z - 3 months ago

Bioventus sees FY26 adjusted EPS 73c-77c, consensus 77c


Bioventus reports Q4 EPS 24c, consensus 22c

2026-03-05T12:13:21.000Z - 3 months ago

Bioventus reports Q4 EPS 24c, consensus 22c


Bioventus initiated with an Outperform at Barrington

2026-02-09T13:00:47.000Z - 4 months ago

Bioventus initiated with an Outperform at Barrington


Bioventus Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 12:45 PM EST - 5 months ago

Bioventus Slides: 44th Annual J.P. Morgan Healthcare Conference


Bioventus Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:30 AM EST - 8 months ago

Bioventus Earnings Call Transcript: Q3 2025


Bioventus Quarterly report: Q3 2025

Nov 4, 2025, 8:30 AM EST - 8 months ago

Bioventus Quarterly report: Q3 2025


Bioventus Earnings release: Q3 2025

Nov 4, 2025, 8:30 AM EST - 8 months ago

Bioventus Earnings release: Q3 2025


Bioventus Slides: Q3 2025

Nov 4, 2025, 8:30 AM EST - 8 months ago

Bioventus Slides: Q3 2025


Bioventus reports Q3 EPS 15c vs 5c last year

2025-11-04T12:41:02.000Z - 8 months ago

Bioventus reports Q3 EPS 15c vs 5c last year


Bioventus sees FY25 EPS 64c-68c

2025-11-04T12:40:38.000Z - 8 months ago

Bioventus sees FY25 EPS 64c-68c


Bioventus Reports Third Quarter Financial Results

Nov 4, 2025, 7:30 AM EST - 8 months ago

Bioventus Reports Third Quarter Financial Results


Bioventus Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 11 months ago

Bioventus Earnings Call Transcript: Q2 2025


Bioventus Quarterly report: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 11 months ago

Bioventus Quarterly report: Q2 2025


Bioventus Earnings release: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 11 months ago

Bioventus Earnings release: Q2 2025


Bioventus Slides: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 11 months ago

Bioventus Slides: Q2 2025


Bioventus reports Q2 EPS 21c, consensus 20c

2025-08-06T11:15:44.000Z - 11 months ago

Bioventus reports Q2 EPS 21c, consensus 20c


Bioventus sees FY25 EPS 64c-68c, consensus 66c

2025-08-06T11:15:32.000Z - 11 months ago

Bioventus sees FY25 EPS 64c-68c, consensus 66c


Bioventus Reports Second Quarter Financial Results

Aug 6, 2025, 7:00 AM EDT - 11 months ago

Bioventus Reports Second Quarter Financial Results


Bioventus enters $400M senior secured credit agreement

2025-08-04T12:15:21.000Z - 11 months ago

Bioventus enters $400M senior secured credit agreement


Bioventus initiated with an Overweight at Cantor Fitzgerald

2025-07-07T10:11:52.000Z - 1 year ago

Bioventus initiated with an Overweight at Cantor Fitzgerald


Bioventus management to meet with Craig-Hallum

2025-06-18T19:30:34.000Z - 1 year ago

Bioventus management to meet with Craig-Hallum


Bioventus Earnings Call Transcript: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Bioventus Earnings Call Transcript: Q1 2025


Bioventus Quarterly report: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Bioventus Quarterly report: Q1 2025


Bioventus Earnings release: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Bioventus Earnings release: Q1 2025


Bioventus Slides: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Bioventus Slides: Q1 2025


Bioventus reports Q1 EPS 8c, consensus 2c

2025-05-06T11:36:41.000Z - 1 year ago

Bioventus reports Q1 EPS 8c, consensus 2c


Bioventus Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Bioventus Proxy statement: Proxy Filing


Bioventus Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Bioventus Proxy statement: Proxy Filing


Bioventus Earnings Call Transcript: Q4 2024

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Bioventus Earnings Call Transcript: Q4 2024


Bioventus Annual report: Q4 2024

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Bioventus Annual report: Q4 2024


Bioventus Earnings release: Q4 2024

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Bioventus Earnings release: Q4 2024


Bioventus Slides: Q4 2024

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Bioventus Slides: Q4 2024


Bioventus Slides: FY 2025

Jan 15, 2025, 1:30 PM EST - 1 year ago

Bioventus Slides: FY 2025


Bioventus Earnings Call Transcript: Q3 2024

Nov 5, 2024, 8:30 AM EST - 1 year ago

Bioventus Earnings Call Transcript: Q3 2024


Bioventus Quarterly report: Q3 2024

Nov 5, 2024, 8:30 AM EST - 1 year ago

Bioventus Quarterly report: Q3 2024


Bioventus Earnings release: Q3 2024

Nov 5, 2024, 8:30 AM EST - 1 year ago

Bioventus Earnings release: Q3 2024


Bioventus Slides: Q3 2024

Nov 5, 2024, 8:30 AM EST - 1 year ago

Bioventus Slides: Q3 2024


Bioventus Registration statement: Registration Filing

Oct 25, 2024, 8:00 AM EDT - 1 year ago

Bioventus Registration statement: Registration Filing


Bioventus Slides: FY 2024

Aug 14, 2024, 9:00 AM EDT - 1 year ago

Bioventus Slides: FY 2024


Bioventus Earnings Call Transcript: Q2 2024

Aug 6, 2024, 8:30 AM EDT - 2 years ago

Bioventus Earnings Call Transcript: Q2 2024


Bioventus Quarterly report: Q2 2024

Aug 6, 2024, 8:30 AM EDT - 2 years ago

Bioventus Quarterly report: Q2 2024


Bioventus Earnings release: Q2 2024

Aug 6, 2024, 8:30 AM EDT - 2 years ago

Bioventus Earnings release: Q2 2024


Bioventus Slides: Q2 2024

Aug 6, 2024, 8:30 AM EDT - 2 years ago

Bioventus Slides: Q2 2024


Bioventus Proxy statement: Proxy Filing

Jun 3, 2024, 8:00 AM EDT - 2 years ago

Bioventus Proxy statement: Proxy Filing


Bioventus Earnings Call Transcript: Q1 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

Bioventus Earnings Call Transcript: Q1 2024


Bioventus Quarterly report: Q1 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

Bioventus Quarterly report: Q1 2024


Bioventus Earnings release: Q1 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

Bioventus Earnings release: Q1 2024


Bioventus Slides: Q1 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

Bioventus Slides: Q1 2024


Bioventus Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Bioventus Proxy statement: Proxy Filing


Bioventus Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Bioventus Proxy statement: Proxy Filing


Bioventus Proxy statement: Proxy Filing

Apr 10, 2024, 8:00 AM EDT - 2 years ago

Bioventus Proxy statement: Proxy Filing


Bioventus Earnings Call Transcript: Q4 2023

Mar 12, 2024, 8:30 AM EDT - 2 years ago

Bioventus Earnings Call Transcript: Q4 2023


Bioventus Annual report: Q4 2023

Mar 12, 2024, 8:30 AM EDT - 2 years ago

Bioventus Annual report: Q4 2023


Bioventus Earnings release: Q4 2023

Mar 12, 2024, 8:30 AM EDT - 2 years ago

Bioventus Earnings release: Q4 2023


Bioventus Slides: Q4 2023

Mar 12, 2024, 8:30 AM EDT - 2 years ago

Bioventus Slides: Q4 2023


Bioventus Earnings Call Transcript: Q3 2023

Nov 7, 2023, 8:30 AM EST - 2 years ago

Bioventus Earnings Call Transcript: Q3 2023


Bioventus Quarterly report: Q3 2023

Nov 7, 2023, 8:30 AM EST - 2 years ago

Bioventus Quarterly report: Q3 2023


Bioventus Earnings release: Q3 2023

Nov 7, 2023, 8:30 AM EST - 2 years ago

Bioventus Earnings release: Q3 2023


Bioventus Slides: Q3 2023

Nov 7, 2023, 8:30 AM EST - 2 years ago

Bioventus Slides: Q3 2023


Bioventus to Present at the Cantor Global Healthcare Conference

Sep 19, 2023, 9:52 PM EDT - 2 years ago

Bioventus to Present at the Cantor Global Healthcare Conference


Bioventus Earnings Call Transcript: Q2 2023

Aug 8, 2023, 8:30 AM EDT - 3 years ago

Bioventus Earnings Call Transcript: Q2 2023


Bioventus Quarterly report: Q2 2023

Aug 8, 2023, 8:30 AM EDT - 3 years ago

Bioventus Quarterly report: Q2 2023


Bioventus Earnings release: Q2 2023

Aug 8, 2023, 8:30 AM EDT - 3 years ago

Bioventus Earnings release: Q2 2023


Bioventus Slides: Q2 2023

Aug 8, 2023, 8:30 AM EDT - 3 years ago

Bioventus Slides: Q2 2023


Bioventus Completes Divestiture of its Wound Business

May 23, 2023, 7:30 AM EDT - 3 years ago

Bioventus Completes Divestiture of its Wound Business


Bioventus Earnings Call Transcript: Q1 2023

May 16, 2023, 5:00 PM EDT - 3 years ago

Bioventus Earnings Call Transcript: Q1 2023


Bioventus Quarterly report: Q1 2023

May 16, 2023, 5:00 PM EDT - 3 years ago

Bioventus Quarterly report: Q1 2023


Bioventus Earnings release: Q1 2023

May 16, 2023, 5:00 PM EDT - 3 years ago

Bioventus Earnings release: Q1 2023


Bioventus Slides: Q1 2023

May 16, 2023, 5:00 PM EDT - 3 years ago

Bioventus Slides: Q1 2023


Bioventus Announces Divestiture of its Wound Business

May 10, 2023, 9:00 AM EDT - 3 years ago

Bioventus Announces Divestiture of its Wound Business


Bioventus Proxy statement: Proxy Filing

Apr 27, 2023, 8:00 AM EDT - 3 years ago

Bioventus Proxy statement: Proxy Filing


Bioventus Proxy statement: Proxy Filing

Apr 27, 2023, 8:00 AM EDT - 3 years ago

Bioventus Proxy statement: Proxy Filing


Bioventus Announces CEO Leadership Change

Apr 5, 2023, 8:00 AM EDT - 3 years ago

Bioventus Announces CEO Leadership Change


Bioventus Earnings Call Transcript: Q4 2022

Mar 31, 2023, 8:30 AM EDT - 3 years ago

Bioventus Earnings Call Transcript: Q4 2022


Bioventus Annual report: Q4 2022

Mar 31, 2023, 8:30 AM EDT - 3 years ago

Bioventus Annual report: Q4 2022


Bioventus Earnings release: Q4 2022

Mar 31, 2023, 8:30 AM EDT - 3 years ago

Bioventus Earnings release: Q4 2022


Bioventus Slides: Q4 2022

Mar 31, 2023, 8:30 AM EDT - 3 years ago

Bioventus Slides: Q4 2022


MarketBeat
MarketBeat Jun. 8 at 11:04 PM
https://marketbeat.com/a/8701425/ $BVS Bioventus Highlights PNS, PRP Growth as Cash Flow Improves and Debt Falls
0 · Reply
Hope2retire
Hope2retire Jun. 1 at 6:01 PM
$BVS It's go to bottom out somewhere here! And someone's gotta start buying this up. I'm buying what I can, but I don't have the juice to make it move. Waiting on the makers. Still bullish on $BVS
1 · Reply
metrostock
metrostock May. 29 at 6:14 PM
$BVS why are trades in the single digits ? Is there manipulation happening ?
0 · Reply
Hope2retire
Hope2retire May. 27 at 4:57 PM
$BVS No news, no catalyst at all to justify this! I don't know why I still bother with any healthcare stocks! They never fail to fail! Someone is gradually dumping heavy chunks over the last 4 or 5 days. Derisking, I guess. Either way, something's got to turn around! And quick!!
2 · Reply
theDIOyears
theDIOyears May. 27 at 2:32 PM
$BVS the bleeding continues. Why? Makes no sense. Someone have any other insight into this action?
1 · Reply
gazza01
gazza01 May. 23 at 1:41 AM
$BVS or maybe it was the results in the Cartistem phrase 3 that showed disease modification in knee OA?
1 · Reply
gazza01
gazza01 May. 22 at 12:03 PM
$BVS I wonder if the drop is derisking, as the results expected in May, for the Australian knee OA stock Cynata ASX:CYP? Their results are targeting disease modification for OA, not just pain relief... If successful, the CYP trial would wipe out treatments just providing pain relief such as hyaluronic acid injections.
0 · Reply
Doozio
Doozio May. 21 at 9:35 PM
$BVS maybe they wud extended a 🐑 🪧 ONTO 🐒🍌🧠⏰♾️
1 · Reply
Doozio
Doozio May. 21 at 6:45 PM
$BVS ONTO 🐒🍌🧠⏰♾️
0 · Reply
gazza01
gazza01 May. 21 at 5:11 PM
$BVS Weird. Can't see any negative news...
1 · Reply
farcanal
farcanal May. 6 at 11:52 AM
$BVS https://ir.bioventus.com/news-releases/news-release-details/bioventus-reports-first-quarter-financial-results-2 ✅ Q1 reported revenue of $132.1 million increased 7% ✅ First quarter GAAP earnings of $0.04 per diluted share compared to the prior-year period loss of $0.04 per diluted share ✅ Non-GAAP earnings* of $0.15 per diluted share compared to $0.08 per diluted share in the prior-year period ✅ Cash from operations of $8.9 million increased $28.3 million compared to the $19.3 million cash outflow in the prior-year period ✅ Company raises Non-GAAP EPS* and Cash from Operations guidance and reaffirms revenue guidance for full year 2026
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 6 at 11:52 AM
$BVS Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.05 up 225.00% YoY • Reported revenue of $132.09M up 6.63% YoY
1 · Reply
farcanal
farcanal May. 6 at 11:45 AM
$BVS And tripled again! What a great turnaround this has been. Q1 revenue up 7%
0 · Reply
SuperGreenToday
SuperGreenToday May. 1 at 12:29 PM
$BVS Share Price: $9.87 Contract Selected: Oct 16, 2026 $10 Calls Buy Zone: $1.78 – $2.20 Target Zone: $2.95 – $3.60 Potential Upside: 56% ROI Time to Expiration: 167 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
History101
History101 Apr. 25 at 6:30 PM
$BVS 441 watching 4/25/2026
0 · Reply
Doozio
Doozio Apr. 23 at 7:28 PM
$BVS Thursday 🐑 🎁 s
0 · Reply
Doozio
Doozio Apr. 14 at 2:23 AM
$BVS out of the tightness ONTO 🐒🍌🧠⏰♾️
0 · Reply
Valuebuilder
Valuebuilder Mar. 17 at 9:47 PM
$BVS Definitely a stock to watch for 2026 as it’s hugely undervalued.Good team in place with a diversified group of products but a complicated story.For the revenue ,margin profile and profitability it’s very cheap on every metric.Has not been discovered by the larger funds yet but when it starts getting attention it can run .
0 · Reply
ClaraDevlin_
ClaraDevlin_ Mar. 6 at 8:42 PM
$BVS value area.
0 · Reply
d_risk
d_risk Mar. 5 at 4:02 PM
$BVS - Bioventus Inc - 10K - Updated Risk Factors BVS overhauled 10-K risks: streamlined financing language; added EGC-to-large issuer, cash concentration, HA/CMS and broader reimbursement and ACA/Medicare cut risks; beefed up IT, cyber, supply chain, litigation, pricing pressure, talent, environmental/sterilization, privacy/export controls and IP litigation disclosures; while dropping explicit competition, branding, training, and some EU MDR detail. #MedicalDevices #HealthcareReimbursement #CybersecurityRisks #SupplyChain #IntellectualProperty 🟢 Added 🟠 Removed https://d-risk.ai/BVS/10-K/2026-03-05
0 · Reply
OpenOutcrier
OpenOutcrier Mar. 5 at 1:45 PM
$BVS (+8.3% pre) Bioventus Earnings Report: Q4 Overview https://ooc.bz/l/95605
0 · Reply